A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

What this study is about

This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD). The primary objective of this study is to assess the efficacy of different doses of SAR441566 compared with placebo in participants with moderate to severe CD. This study will have an anticipated duration of up to 59 weeks which will include a screening period of 4 weeks (+7 calendar days if needed), followed by the Main Study (MS) treatment period, lasting 52 weeks, and a 2-week follow-up period after end of treatment for participants not enrolling in the Long Term Safety (LTS) study. The MS period includes a Double-Blind (DB) treatment period with 12 weeks of induction followed by 40 weeks of maintenance. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants. The combined duration of the DB maintenance and OL periods cannot exceed 40 weeks, depending on when participants switch.

Who can join (things the study team will check)

✅ You may be able to join if…

• Male or female participants aged 18 to 75 years at the time of signing the ICF
• Confirmed diagnosis of CD for at least 3 months prior to Baseline
• Confirmed diagnosis of moderate to severe CD as assessed by:
  • Crohn's Disease Activity Index (CDAI) score and the Simple Endoscopic Score for Crohn's disease (SES-CD) on an endoscopy confirmed by a central reader
  • stool frequency (SF), abdominal pain (AP) score
• History of prior exposure to standard treatment (5-ASA, steroids, immunomodulators or antibiotics) or advanced therapies (biologics or small molecules), but having inadequate response to, loss or response to or intolerance to at least one of these therapies
• On stable doses of standard treatments prior to screening (oral 5-ASA compounds, oral corticosteroids, thiopurines (eg. AZA, 6-MP), or MTX)
• Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Women participants should not be pregnant or breastfeeding.

🚫 You may not be able to join if…

• Participants with active UC, indeterminate colitis or short bowel syndrome
• Participants with CD isolated to the stomach, duodenum, jejunum, or peri anal region, without colonic or ileal involvement
• Participants with following ongoing known complications of CD: fistula, abscess, symptomatic stricture/stenosis, fulminant colitis, toxic megacolon, recent bowel resection within 3 months of screening or history of > 3 bowel resections
• Participants with stool sample positive for infectious pathogens
• Participants with active tuberculosis (TB) or a history of incompletely treated active or latent TB per local guidelines
• Participants with Positive Hepatitis B surface antigen (HBsAg) or positive Hepatitis B core antibody (HBcAb); and/or positive Hepatitis C antibody (HCV) at the Screening Visit
• Participants with any other active, chronic or recurrent infection, including recurrent or disseminated herpes zoster or disseminated herpes simplex
• Participants with a known history of Human Immunodeficiency Virus (HIV) infection or positive HIV-1 or HIV-2 serology at screening
• Participants presenting with active malignancies, lymphoproliferative disease, or recurrence of either, within the 5 years before screening
• History of colonic mucosal dysplasia or presence of colonic mucosal dysplasia or adenomatous colonic polyps not removed during colonoscopy at screening visit
• Infection(s) requiring treatment with IV anti infectives within 30 days or oral/intramuscular anti-infectives within 14 days prior to the screening visit
• Participants requiring or receiving any parental nutrition and/or exclusive enteral nutrition
• Participants who received cyclosporine, tacrolimus, mycophenolate mofetil, or thalidomide within 30 days prior to screening
• Participants who received fecal microbial transplantation within 30 days prior to screening
• Participants who have ever been exposed to natalizumab (Tysabri®) or oral carotegrast methyl (Carogra®)
• Participants who received IV corticosteroids within 14 days prior to screening or during screening period
• Participants who received therapeutic enema or suppository, other than required for colonoscopy within 14 days prior to screening or during screening
• Screening laboratory and other analyses show abnormal results The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where this trial is running

• GI Alliance - Arizona Digestive Health - Sun City- Site Number : 8400020, Sun City, Arizona, United States
• Bristol Hospital- Site Number : 8400007, Bristol, Connecticut, United States
• Novum Research- Site Number : 8400021, Clermont, Florida, United States
• Homestead Associates in Research- Site Number : 8400012, Homestead, Florida, United States
• Clinical Research of Osceola- Site Number : 8400013, Kissimmee, Florida, United States
• Wellness Clinical Research - Miami Lakes - 8181 Northwest 154th Street- Site Number : 8400010, Miami Lakes, Florida, United States
• GCP Clinical Research- Site Number : 8400004, Tampa, Florida, United States
• GI Alliance - Glenview- Site Number : 8400015, Glenview, Illinois, United States
• Illinois Gastroenterology Group- Site Number : 8400011, Gurnee, Illinois, United States
• University of Michigan Health System - Ann Arbor- Site Number : 8400017, Ann Arbor, Michigan, United States
• Gi Alliance - Flowood- Site Number : 8400019, Flowood, Mississippi, United States
• Vector Clinical Trials- Site Number : 8400001, Las Vegas, Nevada, United States

+ 127 more sites.

Who to contact

Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · contact-us@sanofi.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06637631.